NeOnc Technologies (NTHI) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed NeOnc Technologies (NTHI) over the past year, gaining 9.6% versus a loss of 79.1%. Rafael is the larger company by market cap ($82.9 million vs $72.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | RFL |
|---|---|---|
| Share price | $2.50 | $1.60 |
| Market cap | $72.04M | $82.94M |
| 1-day change | -1.15% | +8.74% |
| YTD return | -69.41% | +25.42% |
| 1-year return | -79.07% | +9.63% |
| 5-year return | — | -95.09% |
| EPS (TTM) | $-2.13 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $3.96 |
| 52-week low | $2.50 | $1.12 |
| Distance from 52-week high | -79.31% | -59.72% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +579.73% | — |
| Average volume | 195.17K | 159.84K |
| Shares outstanding | 28.81M | 51.21M |
| Employees | 5 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed NTHI by 88.7 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NTHI vs RFL FAQ
Which is bigger, NeOnc Technologies or Rafael?
Rafael (RFL) is larger, with a market capitalization of $82.94M compared with $72.04M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, NTHI or RFL?
RFL returned +9.63% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.